Glenmark Specialty S A has received approval from the US Food and Drug Administration (US FDA) to expand the use of its allergy treatment RYALTRIS nasal spray for pediatric patients aged 6 to less than 12 years suffering from Seasonal Allergic Rhinitis (SAR). The approval broadens the eligible patient population for the drug in the […]